Background: It has been assumed that continuous glucose sensors show substantial time lags versus blood glucose. Intensive observation of glucose profiles is essential in the achievement of tight glycemic control. Data for each patient on use of OHAs and insulin (type and dose), glycemic control, hypoglycemic episodes, body weight, quality of life, and costs were collected at baseline and 3 and 6 months.For the 18,995 participants who were eligible for baseline analysis, mean±SD age was 55.4±10.4 years, with 52.5% males. doi:10.1089/dia.2015.0133. After 7 days, both types of infusion sets had a 64% failure rate. Weight gain data from this study were analyzed as a function of hypoglycemia frequency. A dose-response relationship between worsening glucose control categories and measures of overall reduced HRV was found.
Thus, we confirmed that our new PI sensor has excellent sensor characteristics in vitro and in vivo. Although a fundamental tool for patients with GDM in terms